Home

Eli Lilly (LLY)

799.57
+0.00 (0.00%)
NYSE · Last Trade: Oct 22nd, 6:29 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Reportfool.com
The rapid growth rates of recent years aren't guaranteed to continue.
Via The Motley Fool · October 22, 2025
Got 1K to Invest? These 3 Stocks Are Still Attractive Buysmarketbeat.com
Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains.
Via MarketBeat · October 21, 2025
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fallfool.com
Don't try to catch a falling surgical knife.
Via The Motley Fool · October 21, 2025
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?fool.com
The tides continue to change in Eli Lilly's favor in the GLP-1 space.
Via The Motley Fool · October 21, 2025
3 Overrated Stocks That Fall Short
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Via StockStory · October 21, 2025
Here's How Much $100 Invested In Eli Lilly 20 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · October 20, 2025
Jim Cramer's Crystal Ball: Unpacking the Market's Top 10 Drivers for a Pivotal Monday
As the financial markets gear up for the week commencing Monday, October 20, 2025, investors are keenly attuned to the insights of CNBC's Jim Cramer, a vocal and influential voice in the stock market. While a precise, real-time "Top 10" list from Cramer for this specific Monday is not publicly
Via MarketMinute · October 20, 2025
Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Resultsinvestors.com
The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.
Via Investor's Business Daily · October 20, 2025
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyondfool.com
These companies are jockeying for position in a potential $150 billion market opportunity.
Via The Motley Fool · October 20, 2025
3 Hyped Up Stocks We Think Twice About
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
Via StockStory · October 20, 2025
J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure Fearsfool.com
Via The Motley Fool · October 19, 2025
Investment Advisor Goes All-In on Big Pharma Stock to the Tune of $1.07 Billion, According to Recent Filingfool.com
Via The Motley Fool · October 19, 2025
Large Wealth Advisor Trims Exposure to Red-Hot Digital Advertising Stockfool.com
Via The Motley Fool · October 19, 2025
Got $5,000? 2 Stocks to Buy Now and Hold for the Long Termfool.com
These two high-quality stocks can deliver impressive returns in the long run.
Via The Motley Fool · October 19, 2025
'No Place Is Risk-Free Until The World Is Polio-Free:' Bill Gates Urges Global Action To Close Deadly Immunity Gapsbenzinga.com
Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.
Via Benzinga · October 19, 2025
Benzinga Bulls And Bears: Stellantis, Papa John's, Oklo — And Trade Tensions Shake Chip Stocksbenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · October 18, 2025
Had You Invested $10,000 in the Vanguard S&P 500 Growth ETF 10 Years Ago, Here's How Much You'd Have Todayfool.com
The Vanguard S&P 500 Growth ETF typically outperforms the S&P 500 over the long term.
Via The Motley Fool · October 18, 2025
Trump's Weight-Loss Drug Push May Put These ETFs On A Dietbenzinga.com
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.
Via Benzinga · October 17, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · October 17, 2025
Why Eli Lilly (LLY) Stock Is Down Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro. 
Via StockStory · October 17, 2025
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032benzinga.com
Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...
Via Benzinga · October 17, 2025
Which S&P500 stocks are moving on Friday?chartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · October 17, 2025
Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.investors.com
Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs.
Via Investor's Business Daily · October 17, 2025
Market Jitters: Dow Dips Amid Bank Fears While Eli Lilly and Novo Nordisk Tumble on Trump's Drug Pricing Comments
The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently, pharmaceutical giants Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) saw their shares plummet following a new round of
Via MarketMinute · October 17, 2025
Eli Lilly Shares Are Trading Lower Friday: What's Going On?benzinga.com
Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price.
Via Benzinga · October 17, 2025